Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

NCT07269249 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT07269249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer
Lead sponsor
National Cancer Institute, Naples
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2025
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer (larc)